|
1）Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15: 7412-20
|
|
|
|
2）Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol . 2012; 30: 2046-54
|
|
|
|
|
|
3）Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013; 24: 75-83
|
|
|
|
|
|
4）Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30: 2691-7
|
|
|
|
|
|
5）Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-64
|
|
|
|
|
|
6）Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013; 34: 556-63
|
|
|
|
|
|
7）Brahmer JR, Horn L, Gandhi L, et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis: results from a phase 1b study. J Clin Oncol. 2014; 32(Suppl 15): abstract 8112
|
|
|
|
|
|
8）Gettinger S, Shepherd FA, Antonia SJ, et al. First-line Nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol. 2014; 32(Suppl 15): abstract 8024
|
|
|
|
|
|
9）Rizvi NA, Garon EB, Patnaik A, et al. Safety and clinical activity of pembrolizumab (MK-3475) as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014; 32(Suppl 15): abstract 8007
|
|
|
|
|
|
10）Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of pembrolizumab (MK-3475) in previously treated patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2014; 32(Suppl 15): abstract 8020
|
|
|
|
|
|
11）Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366: 2455-65
|
|
|
|
|
|
12）Spigel DR, Gettinger SN, Horn L, et al Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 2013; 31(Suppl.15), Abstract 8008
|
|
|
|
|
|
13）Rizvi NA, Chow LQ, Dirix LY, et al. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol. 2014; 32(Suppl 15): abstract TPS8123
|
|
|
|
|
|
14）Brahmer J, Rizvi N, Lutzky J, et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin Oncol. 2014; 32(Suppl 15): abstract TPS8021
|
|
|
|
|
|
15）Antonia SJ, Brahmer JR, Gettinger S, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014; 32(Suppl 15): abstract 8113
|
|
|
|
|
|
16）Rizvi NA, Chow LQ, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014; 32(Suppl 15): abstract 8022
|
|
|
|
|
|
17）Antonia SJ, Gettinger S, Chow LQ, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line non-small cell lung cancer (NSCLC): interim phase 1 results. J Clin Oncol. 2014; 32(Suppl 15): abstract 8023
|
|
|
|
|
|
18）Gao X, Zhu Y, Li G, et al. TIM-3 expression characterizes regulatory T cells tumor tissues and is associated with lung cancer progression. PLoS One. 2012; 7: e30676
|
|
|
|
|
|
19）Ngiow SF, Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011; 71: 3540-51
|
|
|
|
|
|
20）Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004; 21: 503-13
|
|
|
|
|
|
21）Foy SP, Rountree RB, Cote J, et al. Antitumor efficacy of poxvirus-based active immunotherapy alone and in combination with subtherapeutic dosing with immune checkpoint inhibitors. J Clin Oncol. 2014; 32(Suppl 15): abstract 3058
|
|
|
|
|
|
22）Segal NH, Hodi FS, Sanborn RE, et al. A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors. J Clin Oncol. 2014; 32(Suppl 15): abstract TPS3115
|
|
|
|
|
|
23）Rizvi NA, Infante JR, Gibney GT, et al. A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (pts) with select advanced solid tumors. J Clin Oncol. 2013; 31(Suppl 15): abstract TPS3106
|
|
|
|
|
|
24）Curti BD, Kovacsovics-Bankowski M, Morris N, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 2013; 73: 7189-98
|
|
|
|
|
|
25）Melero I, Gangadhar TC, Kohrt HE, et al. A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-hodgkin’s lymphoma (B-NHL). J Clin Oncol. 2013; 31(Suppl 15): abstract TPS3107
|
|
|
|
|
|
26）Schaer DA, Murphy JT, Wolchok JD. Modulation of GITR for cancer immunotherapy. Curr Opin Immunol. 2012; 24: 217-24
|
|
|
|
|